AUTHOR=Cozzi Martina , Donato Paola , Ugolini Gabriele , Nguefouet Momo Rostand Emmanuel , Nacchia Francesco , Ballarini Zeno , Piccoli Pierluigi , Cantini Maurizio , Caletti Chiara , Andreola Stefano , Gandini Giorgio , Gambaro Giovanni , Boschiero Luigino 

TITLE=Outcomes in AB0 Incompatible Living Donor Kidney Transplantation: A Case – Control Study

JOURNAL=Frontiers in Medicine

VOLUME=9

YEAR=2022

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.932171

DOI=10.3389/fmed.2022.932171

ISSN=2296-858X

ABSTRACT=<sec><title>Background</title><p>Patients waiting for a kidney transplant by far exceed available organs. AB0 incompatible living donor kidney transplantation (AB0i LDKT) represents an additional therapeutic strategy, but with higher risk for complications. We aimed at evaluating outcomes of AB0i LDKTs compared to compatible (AB0c) controls at our Institution.</p></sec><sec><title>Methods</title><p>Retrospective matched case – control study (1:2) comparing AB0i vs. AB0c LDKTs from March 2012 to September 2021. Considered outcomes: graft function, acute rejection, sepsis, CMV infection, BK virus reactivation, death-censored graft survival, patient survival.</p></sec><sec><title>Results</title><p>Seventeen AB0i LDKTs matched to 34 AB0c controls. We found excellent graft function, comparable in the two groups, at all considered intervals, with an eGFR (ml/min/1.73 m<sup>2</sup>) of 67 vs. 66 at 1 year (<italic>p</italic> = 0.41), 63 vs. 64 at 3 years (<italic>p</italic> = 0.53). AB0i recipients had a statistically significant higher incidence of acute rejection, acute antibody-mediated rejection and sepsis within 30 days (<italic>p</italic> = 0.016; <italic>p</italic> = 0.02; <italic>p</italic> = 0.001), 1 year (<italic>p</italic> = 0.012; <italic>p</italic> = 0.02; <italic>p</italic> = 0.0004) and 3 years (<italic>p</italic> = 0.004; <italic>p</italic> = 0.006; <italic>p</italic> = 0.012) after surgery. There was no difference in CMV infection, BK virus reactivation, death-censored graft survival between the two groups. Patient survival was inferior in AB0i group at 1 and 3 years (88.2 vs. 100%; log-rank <italic>p</italic> = 0.03) due to early death for opportunistic infections. AB0i LDKTs spent longer time on dialysis (<italic>p</italic> = 0.04) and 82.3 vs. 38.3% controls had blood group 0 (<italic>p</italic> = 0.003).</p></sec><sec><title>Conclusions</title><p>AB0i LDKT is an effective therapeutic strategy with graft function and survival comparable to AB0c LDKTs, despite higher rates of acute rejection and sepsis. It is an additional opportunity for patients with less chances of being transplanted, as blood group 0 individuals.</p></sec>